Eculizumab-Induced Acute Heart Failure Decompensation in a Patient with Clinically Suspected Complement-Mediated Thrombotic Microangiopathy: A Case Report
{{output}}
Eculizumab is a highly effective and generally safe therapy for atypical hemolytic uremic syndrome (aHUS), a rare subtype of thrombotic microangiopathy (TMA). This report presents a case of recurrent episodes of acute decompensated heart failure temporally rel... ...
